Abstract
This commentary takes up Pearl's welcome challenge to clearly articulate the scientific value of principal stratification estimands that we and colleagues have investigated, in the area of randomized placebo-controlled preventive vaccine efficacy trials, especially trials of HIV vaccines. After briefly arguing that certain principal stratification estimands for studying vaccine effects on post-infection outcomes are of genuine scientific interest, the bulk of our commentary argues that the "causal effect predictiveness" (CEP) principal stratification estimand for evaluating immune biomarkers as surrogate endpoints is not of ultimate scientific interest, because it evaluates surrogacy restricted to the setting of a particular vaccine efficacy trial, but is nevertheless useful for guiding the selection of primary immune biomarker endpoints in Phase I/II vaccine trials and for facilitating assessment of transportability/bridging surrogacy.
| Original language | English (US) |
|---|---|
| Article number | 36 |
| Journal | International Journal of Biostatistics |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2011 |
Bibliographical note
Funding Information:Author Notes: We thank the reviewer for extraordinarily insightful comments that led to major improvements. This research was supported by NIH NIAID grant 2 R37 AI054165-08 and NIAID HIV Vaccine Trials Network grant 5 U01 AI068635-05.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- causal inference
- principal stratification
- vaccine trial
Fingerprint
Dive into the research topics of 'Commentary on "principal stratification - A goal or a tool?" by Judea Pearl'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS